ENG
Gastric Cancer Therapy Market: Global Industry Analysis and Forecast (2023-2029) by Therapy Type, End-User, and Region
Gastric Cancer Therapy Market size was valued at US$ 3.49 Billion in 2022 and the Gastric Cancer Therapy revenue is expected to grow at 15% through 2023 to 2029, reaching nearly US$ 9.77 Billion
Format : PDF | Report ID : SMR_416
Gastric Cancer Therapy Market Definition & Overview:
Gastric cancer, also known as stomach cancer, is defined by an increase in the number of malignant cells in the stomach lining. This form of cancer is notoriously difficult to detect since it seldom manifests symptoms in the early stages in most people. In comparison to other types of cancer, stomach cancer is quite uncommon. Other illnesses and disorders that contribute to gastric cancer include lymphoma, tumors in other regions of the digestive system, stomach polyps, and many more. The report on gastric cancer therapy market icludes segment analysis on the basis of the therapy type, end-user and region.
Gastric Cancer Therapy Market Dynamics:
The number of persons diagnosed with gastric cancer has grown as the number of obese people and smokers has increased. Gastric cancer is increased when people use tobacco and eat an unhealthy diet. According to the American Institute for Cancer Research, there will be roughly 27,600 instances of Gastric cancer detected in 2020. (16,980 in men and 10,620 in women). The gastric cancer therapy market is expected grow with increase in the number of cases of gastric cancer.
The gastric cancer therapy market is constrained by strict laws and standards for medication approval. The drug regulatory board in each region establishes its own set of rules, guidelines, and regulations. The USFDA standards for American medicines, for example, stipulate a number of conditions relating to the drug's safety and efficacy, as well as some labeling requirements. Similarly, before authorized pharmaceuticals may be sold or commercialized on the European continent, the European Medicines Agency (EMA) issues licenses. Teysuno, a medicine for advanced stomach cancer, may only be purchased with a valid prescription, and every firm is required to examine the consequences of using Teysuno and to identify the measures that patients and healthcare professionals should take to reduce any potential adverse effects. The gastric cancer therapy market is hampered by these rules.
Gastric Cancer Therapy Market Segment Analysis:
By Therapy Type, Chemotherapy is the most prevalent type of treatment for cancer cells that are meant to stop or decrease their proliferation. Chemotherapy works by eliminating, destroying, or damaging cancer cells in a specific region, whereas surgery and radiation treatment function across the body. Chemotherapy can therefore kill and harm cancer cells that have spread to other areas of the body, distant from the initial tumor. Chemotherapy is still the treatment of choice for most oncologists across the world, despite its numerous negative effects. It is also inexpensive when compared to immunotherapies, and it may be given intravenously or orally. According to GLOBOCAN estimations, the greatest rate of gastric cancer in 2018 was in South Korea, followed by Mongolia. Similarly, in 2019, the stomach cancer rate in South Korea was 57.8% in males and 23.5 percent in women.
Gastric Cancer Therapy Market Regional Insights:
Asia-Pacific gastric cancer therapy market generated USD 1.01 billion in revenue in 2020. The primary cause for this is an increase in the number of instances of stomach cancer, particularly in India and China. According to the World Health Organization (WHO), China had 456,124 cases of stomach cancer in 2018. This, together with the increasing frequency of new product introductions, is moving the regional market forward.
In North America, the rising demand for gastric cancer medications is being driven by an increasing desire for targeted therapy, an increase in the prevalence of stomach cancer, and increased R&D activities by pharmaceutical companies. Government support and good health reimbursement rules will bode well for the European gastric carcinoma therapy sector.
The objective of the report is to present a comprehensive analysis of the Gastric Cancer Therapy Market to the stakeholders in the industry. The report provides trends that are most dominant in the Gastric Cancer Therapy Market and how these trends will influence new Business investments and market development throughout the forecast period. The report also aids in the comprehension of the market dynamics and competitive structure of the market by analyzing market leaders, market followers, and regional players.
The qualitative and quantitative data provided in the Gastric Cancer Therapy Market report is to help understand which market segments, regions are expected to grow at higher rates, factors affecting the market, and key opportunity areas, which will drive the industry and market growth through the forecast period. The report also includes the competitive landscape of key players in the industry along with their recent developments in the Gastric Cancer Therapy Market. The report studies factors such as company size, market share, market growth, revenue, production volume, and profits of the key players in the market.
The report provides Porter's Five Force Model, which helps in designing the business strategies in the market. The report helps in identifying how many rivals are existing, who they are, and how their product quality is in the Market. The report also analyses if the Gastric Cancer Therapy Market is easy for a new player to gain a foothold in the market, do they enter or exit the market regularly if the market is dominated by a few players, etc.
Gastric Cancer Therapy Market Scope:
|
Gastric Cancer Therapy Market Scope |
|
|
Market Size in 2022 |
USD 3.49 Bn. |
|
Market Size in 2029 |
USD 9.77 Bn. |
|
CAGR (2023-2029) |
15% |
|
Historic Data |
2017-2021 |
|
Base Year |
2022 |
|
Forecast Period |
2023-2029 |
|
Segment Scope |
by therapy Type
|
|
By End-Use
|
|
|
Regional Scope |
North America- United States, Canada, and Mexico Europe – UK, France, Germany, Italy, Spain, Sweden, Austria, and Rest of Europe Asia Pacific – China, India, Japan, South Korea, Australia, ASEAN, Rest of APAC Middle East and Africa - South Africa, GCC, Egypt, Nigeria, Rest of the Middle East and Africa South America – Brazil, Argentina, Rest of South America |
Gastric Cancer Therapy Market Players:
- Bristol-Myers Squibb AB (Sweden)
- Celltrion Inc. (South Korea)
- Eli Lilly and Company (United States)
- Hoffmann-La Roche Ltd. (Switzerland)
- GlaxoSmithKline PLC (United Kingdom)
- Imugene Limited (Australia)
- Novartis AG (Switzerland)
- Merck & Co. Inc. (United States)
- Otsuka Holdings Co. Ltd (Japan)
- Pfizer Inc. (United States)
- Array Biopharma Inc. (United States)
- AstraZeneca PLC (United Kingdom)
Frequently Asked Questions
The market for gastric cancer medications will be driven by an increase in the number of cases of gastric cancer.
Asia-Pacific generated USD 1.01 billion in revenue in 2020.
In North America, the rising demand for gastric cancer medications is being driven by an increasing desire for targeted therapy, an increase in the prevalence of stomach cancer, and increased R&D activities by pharmaceutical companies.
Bristol-Myers Squibb AB (Sweden), Celltrion Inc. (South Korea), Eli Lilly and Company (United States), Hoffmann-La Roche Ltd. (Switzerland), and GlaxoSmithKline PLC (United Kingdom).
Chapter 1 Scope of the Report
Chapter 2 Research Methodology
2.1. Research Process
2.2. Global Gastric Cancer Therapy Market: Target Audience
2.3. Global Gastric Cancer Therapy Market: Primary Research (As per Client Requirement)
2.4. Global Gastric Cancer Therapy Market: Secondary Research
Chapter 3 Executive Summary
Chapter 4 Competitive Landscape
4.1. Market Share Analysis, By Region, 2022-2029(In %)
4.1.1.1. North America Market Share Analysis, By Value, 2022-2029 (In %)
4.1.1.2. Europe Market Share Analysis, By Value, 2022-2029 (In %)
4.1.1.3. Asia Pacific Market Share Analysis, By Value, 2022-2029 (In %)
4.1.1.4. South America Market Share Analysis, By Value, 2022-2029 (In %)
4.1.1.5. Middle East and Africa Market Share Analysis, By Value, 2022-2029 (In %)
4.2. Market Dynamics
4.2.1. Market Drivers
4.2.2. Market Restraints
4.2.3. Market Opportunities
4.2.4. Market Challenges
4.2.5. PESTLE Analysis
4.2.6. PORTERS Five Force Analysis
4.2.7. Value Chain Analysis
4.3. Global Gastric Cancer Therapy Market Segmentation Analysis, 2022-2029 (Value US$ MN)
4.3.1.1. Global Market Share Analysis, By Therapy Type, 2022-2029 (Value US$ MN)
4.3.1.1.1.Chemotherapy
4.3.1.1.2.Targeted Therapy
4.3.1.1.3.Immunotherapy
4.3.1.1.4.Radiation Therapy
4.3.1.1.5.Surgery
4.3.1.2. Global Market Share Analysis, By End-User, 2022-2029 (Value US$ MN)
4.3.1.2.1.Ambulatory Surgery Centers
4.3.1.2.2.Hospitals and Specialty Clinics
4.3.1.2.3.Other End-users
4.4. North America Gastric Cancer Therapy Market Segmentation Analysis, 2022-2029 (Value US$ MN)
4.4.1.1. North America Market Share Analysis, By Therapy Type, 2022-2029 (Value US$ MN)
4.4.1.1.1.Chemotherapy
4.4.1.1.2.Targeted Therapy
4.4.1.1.3.Immunotherapy
4.4.1.1.4.Radiation Therapy
4.4.1.1.5.Surgery
4.4.1.2. North America Market Share Analysis, By End-User, 2022-2029 (Value US$ MN)
4.4.1.2.1.Ambulatory Surgery Centers
4.4.1.2.2.Hospitals and Specialty Clinics
4.4.1.2.3.Other End-users
4.4.1.3. North America Market Share Analysis, By Country, 2022-2029 (Value US$ MN)
4.4.1.3.1.US
4.4.1.3.2.Canada
4.4.1.3.3.Mexico
4.5. Europe Gastric Cancer Therapy Market Segmentation Analysis, 2022-2029 (Value US$ MN)
4.5.1.1. Europe Market Share Analysis, By Therapy Type, 2022-2029 (Value US$ MN)
4.5.1.2. Europe Market Share Analysis, By End-User, 2022-2029 (Value US$ MN)
4.5.1.3. Europe Market Share Analysis, By Country, 2022-2029 (Value US$ MN)
4.5.1.3.1.UK
4.5.1.3.2.France
4.5.1.3.3.Germany
4.5.1.3.4.Italy
4.5.1.3.5.Spain
4.5.1.3.6.Sweden
4.5.1.3.7.Austria
4.5.1.3.8.Rest Of Europe
4.6. Asia Pacific Gastric Cancer Therapy Market Segmentation Analysis, 2022-2029 (Value US$ MN)
4.6.1.1. Asia Pacific Market Share Analysis, By Therapy Type, 2022-2029 (Value US$ MN)
4.6.1.2. Asia Pacific Market Share Analysis, By End-User, 2022-2029 (Value US$ MN)
4.6.1.3. Asia Pacific Market Share Analysis, By Country, 2022-2029 (Value US$ MN)
4.6.1.3.1.China
4.6.1.3.2.India
4.6.1.3.3.Japan
4.6.1.3.4.South Korea
4.6.1.3.5.Australia
4.6.1.3.6.ASEAN
4.6.1.3.7.Rest Of APAC
4.7. South America Gastric Cancer Therapy Market Segmentation Analysis, 2022-2029 (Value US$ MN)
4.7.1.1. South America Market Share Analysis, By Therapy Type, 2022-2029 (Value US$ MN)
4.7.1.2. South America Market Share Analysis, By End-User, 2022-2029 (Value US$ MN)
4.7.1.3. South America Market Share Analysis, By Country, 2022-2029 (Value US$ MN)
4.7.1.3.1.Brazil
4.7.1.3.2.Argentina
4.7.1.3.3.Rest Of South America
4.8. Middle East and Africa Gastric Cancer Therapy Market Segmentation Analysis, 2022-2029 (Value US$ MN)
4.8.1.1. Middle East and Africa Market Share Analysis, By Therapy Type, 2022-2029 (Value US$ MN)
4.8.1.2. Middle East and Africa Market Share Analysis, By End-User, 2022-2029 (Value US$ MN)
4.8.1.3. Middle East and Africa Market Share Analysis, By Country, 2022-2029 (Value US$ MN)
4.8.1.3.1.South Africa
4.8.1.3.2.GCC
4.8.1.3.3.Egypt
4.8.1.3.4.Nigeria
4.8.1.3.5.Rest Of ME&A
Chapter 5 Stellar Competition Matrix
5.1.1. Global Stellar Competition Matrix
5.1.2. North America Stellar Competition Matrix
5.1.3. Europe Stellar Competition Matrix
5.1.4. Asia Pacific Stellar Competition Matrix
5.1.5. South America Stellar Competition Matrix
5.1.6. Middle East and Africa Stellar Competition Matrix
5.2. Key Players Benchmarking
5.2.1. Key Players Benchmarking By Application, Pricing, Market Share, Investments, Expansion Plans, Physical Presence and Presence in the Market.
5.3. Mergers and Acquisitions in Industry
5.3.1. M&A by Region, Value and Strategic Intent
Chapter 6 Company Profiles
6.1. Key Players
6.1.1. Novartis AG.
6.1.1.1. Company Overview
6.1.1.2. Source Portfolio
6.1.1.3. Financial Overview
6.1.1.4. Business Strategy
6.1.1.5. Key Developments
6.1.2. Bristol-Myers Squibb AB
6.1.3. Celltrion Inc.
6.1.4. Eli Lilly and Company
6.1.5. Hoffmann-La Roche Ltd.
6.1.6. GlaxoSmithKline PLC
6.1.7. Imugene Limited
6.1.8. Novartis AG
6.1.9. Merck & Co. Inc.
6.1.10. Otsuka Holdings Co. Ltd
6.1.11. Pfizer Inc.
6.1.12. Array Biopharma Inc.
6.1.13. AstraZeneca PLC
6.2. Key Findings
6.3. Recommendations
